116 related articles for article (PubMed ID: 16079485)
21. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
Espinel-Ingroff A
Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
[TBL] [Abstract][Full Text] [Related]
22. In vitro antifungal activity of novel azole derivatives with a morpholine ring, UR-9746 and UR-9751, and comparison with fluconazole.
Stevens DA; Aristizabal BH
Diagn Microbiol Infect Dis; 1997 Oct; 29(2):103-6. PubMed ID: 9368086
[TBL] [Abstract][Full Text] [Related]
23. In vitro activity of terbinafine against medically important non-dermatophyte species of filamentous fungi.
Garcia-Effron G; Gomez-Lopez A; Mellado E; Monzon A; Rodriguez-Tudela JL; Cuenca-Estrella M
J Antimicrob Chemother; 2004 Jun; 53(6):1086-9. PubMed ID: 15102749
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo activities of HQQ-3, a new triazole antifungal agent.
Zhao JX; Cao YY; Quan H; Liu CM; He QQ; Wu QY; Gao PH; Cao YB; Liu WX; Jiang YY
Biol Pharm Bull; 2006 Oct; 29(10):2031-4. PubMed ID: 17015946
[TBL] [Abstract][Full Text] [Related]
25. A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity.
Hof H
Mycoses; 2006; 49 Suppl 1():2-6. PubMed ID: 16961575
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and in vitro antifungal activities of novel triazole antifungal agent CS-758.
Konosu T; Oida S; Nakamura Y; Seki S; Uchida T; Somada A; Mori M; Harada Y; Kamai Y; Harasaki T; Fukuoka T; Ohya S; Yasuda H; Shibayama T; Inoue S; Nakagawa A; Seta Y
Chem Pharm Bull (Tokyo); 2001 Dec; 49(12):1647-50. PubMed ID: 11767091
[TBL] [Abstract][Full Text] [Related]
27. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
[TBL] [Abstract][Full Text] [Related]
28. In vitro susceptibility of chromoblastomycosis and phaeohyphomycosis agents to antifungal drugs.
Caligiorne RB; Resende MA; Melillo PH; Peluso CP; Carmo FH; Azevedo V
Med Mycol; 1999 Dec; 37(6):405-9. PubMed ID: 10647121
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of voriconazole against selected fungi.
McGinnis MR; Pasarell L; Sutton DA; Fothergill AW; Cooper CR; Rinaldi MG
Med Mycol; 1998 Aug; 36(4):239-42. PubMed ID: 9776841
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and biological evaluation of novel 1, 2, 4-triazole derivatives as antifungal agent.
Chai X; Yu S; Jiang Y; Zou Y; Wu Q; Zhang D; Jiang Y; Cao Y; Sun Q
Arch Pharm Res; 2012 Nov; 35(11):1895-901. PubMed ID: 23212630
[TBL] [Abstract][Full Text] [Related]
31. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.
Pfaller MA; Messer SA; Hollis RJ; Jones RN
Antimicrob Agents Chemother; 2001 Oct; 45(10):2862-4. PubMed ID: 11557481
[TBL] [Abstract][Full Text] [Related]
32. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.
Pfaller MA; Messer SA; Boyken L; Rice C; Tendolkar S; Hollis RJ; Diekema DJ
J Clin Microbiol; 2007 Jan; 45(1):70-5. PubMed ID: 17079501
[TBL] [Abstract][Full Text] [Related]
33. Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections.
Carrillo-Muñoz AJ; Quindós G; Ruesga M; Alonso R; del Valle O; Hernández-Molina JM; McNicholas P; Loebenberg D; Santos P
J Antimicrob Chemother; 2005 Mar; 55(3):317-9. PubMed ID: 15705637
[TBL] [Abstract][Full Text] [Related]
34. Comparison of in vitro activities of antifungal drugs and ethanolic extract of propolis against Trichophyton rubrum and T. mentagrophytes by using a microdilution assay.
Koc AN; Silici S; Ayangil D; Ferahbaş A; Cankaya S
Mycoses; 2005 May; 48(3):205-10. PubMed ID: 15842339
[TBL] [Abstract][Full Text] [Related]
35. Azole antifungal agents related to naftifine and butenafine.
Castellano S; La Colla P; Musiu C; Stefancich G
Arch Pharm (Weinheim); 2000 Jun; 333(6):162-6. PubMed ID: 10909187
[TBL] [Abstract][Full Text] [Related]
36. Two mechanisms of butenafine action in Candida albicans.
Iwatani W; Arika T; Yamaguchi H
Antimicrob Agents Chemother; 1993 Apr; 37(4):785-8. PubMed ID: 8494375
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.
Yamazaki T; Inagaki Y; Fujii T; Ohwada J; Tsukazaki M; Umeda I; Kobayashi K; Shimma N; Page MG; Arisawa M
Int J Antimicrob Agents; 2010 Oct; 36(4):324-31. PubMed ID: 20674282
[TBL] [Abstract][Full Text] [Related]
38. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species.
Ryder NS; Leitner I
Med Mycol; 2001 Feb; 39(1):91-5. PubMed ID: 11270414
[TBL] [Abstract][Full Text] [Related]
39. Impact of Homologous Resistance Mutations from Pathogenic Yeast on Saccharomyces cerevisiae Lanosterol 14α-Demethylase.
Sagatova AA; Keniya MV; Tyndall JDA; Monk BC
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263059
[TBL] [Abstract][Full Text] [Related]
40. Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus.
Wiederhold NP; Patterson HP; Tran BH; Yates CM; Schotzinger RJ; Garvey EP
J Antimicrob Chemother; 2018 Feb; 73(2):404-408. PubMed ID: 29190379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
